MedPath

Darolutamide Shows Promising Results in Treating Metastatic Hormone-Sensitive Prostate Cancer

a year ago1 min read
Share
In the realm of prostate cancer treatment, serum tumor markers play a pivotal role, especially prostate-specific antigen (PSA), which is highly sensitive and specific post-definitive local therapy. It can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease, guiding curative-intent salvage therapies like salvage radiation upon biochemical recurrence (BCR).
A significant breakthrough comes from the ARASENS trial (NCT02799602), where darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel demonstrated a 32.5% reduction in the risk of death (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared to placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). This trial underscores the potential of darolutamide as a formidable option in the treatment landscape for mHSPC, offering new hope for patients battling this aggressive form of prostate cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

© Copyright 2025. All Rights Reserved by MedPath